Damora Therapeutics (DMRA) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Damora Therapeutics (DMRA) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 38.5% versus a loss of 15.0%. Damora Therapeutics is the larger company by market cap ($1.44 billion vs $1.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMRA | RAPP |
|---|---|---|
| Share price | $23.22 | $23.16 |
| Market cap | $1.44B | $1.37B |
| 1-day change | -4.44% | -1.82% |
| YTD return | +0.91% | -23.67% |
| 1-year return | +38.46% | -15.01% |
| 5-year return | -68.83% | — |
| P/E ratio (TTM) | 13.58 | — |
| EPS (TTM) | $1.71 | $-3.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-209.84M | $-111.48M |
| 52-week high | $38.33 | $52.93 |
| 52-week low | $15.76 | $22.06 |
| Distance from 52-week high | -39.41% | -56.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +101.46% | +177.25% |
| Average volume | 584.28K | 790.62K |
| Shares outstanding | 61.90M | 59.28M |
| Employees | 7 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMRA has outperformed RAPP by 53.5 percentage points over the past year.
About Damora Therapeutics
DMRA stock →Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
DMRA vs RAPP FAQ
Which is bigger, Damora Therapeutics or Rapport Therapeutics?
Damora Therapeutics (DMRA) is larger, with a market capitalization of $1.44B compared with $1.37B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, DMRA or RAPP?
DMRA returned +38.46% over the past 12 months, compared with -15.01% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are Damora Therapeutics and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.